2024
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
Jha M, Wilkinson S, Krishnan K, Collins K, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew S, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression. JAMA Network Open 2024, 7: e2417786. PMID: 38916891, PMCID: PMC11200139, DOI: 10.1001/jamanetworkopen.2024.17786.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDepressive Disorder, Treatment-ResistantElectroconvulsive TherapyFemaleHumansKetamineMaleMiddle AgedTreatment OutcomeConceptsTreatment-resistant depressionQIDS-SR16 scoresElectroconvulsive therapy groupElectroconvulsive therapyQIDS-SR16Measure of premorbid intelligencePosttraumatic stress disorder diagnosisTrial of electroconvulsive therapyNonpsychotic depressive episodeImpaired memory recallAssociated with differential improvementStress disorder diagnosisIntravenous ketamineEnd-of-treatment visitInfusion of ketamineMADRS scorePremorbid intelligenceResistant depressionDepressive episodeMeasures mixed-effects modelsFalse discovery rate adjustmentDisorder diagnosisMemory recallSevere depressionDifferential improvement
2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchConceptsTreatment-resistant major depressionPatient-reported qualityElectroconvulsive therapyMajor depressionECT groupKetamine groupTreatment phaseMusculoskeletal adverse effectsSubanesthetic intravenous ketamineWeeks of treatmentInitial treatment phaseIntravenous ketamineSecondary outcomesPrimary outcomeNoninferiority marginTrial groupECT clinicsNoninferiority trialPatientsComparative effectivenessKetamineClinical sitesAdverse effectsDepressionThree timesEffects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study.
Wilkinson S, Sint K, Forester B, Rhee T. Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36700843, DOI: 10.4088/jcp.22m14583.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAgedDementiaDepressionElectroconvulsive TherapyFollow-Up StudiesHumansMedicareTreatment OutcomeUnited StatesConceptsElectroconvulsive therapyFunctional outcomeComorbid depressionPrincipal psychiatric diagnosisRandomized clinical trialsECT cohortECT patientsComparable cohortsSafe treatmentClinical trialsMedicare patientsCurrent treatmentFunctional declineLimited efficacyPropensity score methodsPsychiatric disordersSummary scoresPsychiatric diagnosisLarger sample sizeMultivariate analysisPsychological symptomsDementiaPatientsOlder adultsCohort
2022
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry 2022, 79: 1162-1172. PMID: 36260324, PMCID: PMC9582972, DOI: 10.1001/jamapsychiatry.2022.3352.Peer-Reviewed Original ResearchMeSH KeywordsDepressive Disorder, MajorElectroconvulsive TherapyHumansKetamineRandomized Controlled Trials as TopicSuicide, AttemptedConceptsStandardized mean differenceMajor depressive episodeSerious adverse eventsElectroconvulsive therapyAdverse eventsDepressive episodeClinical trialsDepression severityEfficacy outcomesSystematic reviewUnique adverse effect profileMeta-analyses (PRISMA) reporting guidelinesSafety of ketamineAdverse effect profileData extractionEuropean clinical trialsDiagnosis of depressionModerate methodological qualityMedical Subject Headings termsPreferred Reporting ItemsCognition/memoryRandom-effects modelSubject Headings termsAcute phaseEffect profile
2018
Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression
Wilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB. Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression. Biological Psychiatry 2018, 85: 454-465. PMID: 30528745, PMCID: PMC6380941, DOI: 10.1016/j.biopsych.2018.09.004.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsBehavior TherapyCombined Modality TherapyDepressionElectroconvulsive TherapyHumansNeuronal PlasticityTranscranial Magnetic StimulationConceptsClinical outcomesN-methyl-D-aspartate receptor modulatorsLong-term clinical outcomesLong-term treatment outcomesBehavioral interventionsImpairment of neuroplasticityUnderstanding of pathophysiologyStand-alone treatmentTranscranial brain stimulationNeuroplasticity deficitsSymptom burdenElectroconvulsive therapyReceptor modulatorsTreatment outcomesEnhanced neuroplasticityMood disordersDepressive symptomsBrain stimulationTreatment approachesSymptom reductionNeuroplasticityNeuropsychiatric disordersBehavioral therapyDisease statesTherapeutic developmentIdentifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans
Wilkinson ST, Agbese E, Leslie DL, Rosenheck RA. Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans. Psychiatric Services 2018, 69: 542-548. PMID: 29385954, PMCID: PMC6248332, DOI: 10.1176/appi.ps.201700364.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBipolar DisorderDatabases, FactualDepressive Disorder, MajorElectroconvulsive TherapyFemaleHumansInsurance, HealthMaleMiddle AgedMultimorbidityUnited StatesYoung AdultConceptsElectroconvulsive therapyMood disordersClinical characteristicsECT useUse of ECTCharacteristics of patientsProportion of patientsComorbid psychiatric disordersMajor depressive disorderNumber of prescriptionsSubstance use disordersOutpatient psychotherapy visitsECT patientsECT utilization rateMarketScan databasePsychotherapy visitsPsychotropic medicationsDepressive disorderPsychiatric disordersService useUse disordersPatientsECT utilizationBipolar disorderCommercial insurance
2017
Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy
Wilkinson ST, Ostroff RB, Sanacora G. Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy. Journal Of Ect 2017, 33: 52-57. PMID: 27564424, PMCID: PMC5315599, DOI: 10.1097/yct.0000000000000348.Peer-Reviewed Original ResearchConceptsComputer-assisted cognitive-behavior therapyElectroconvulsive therapyCognitive behavior therapyMean timeOpen-label trialMajor depressive episodeMean numberBehavior therapyAcute treatmentDepressive episodeIndex coursePrevent relapseDepression severityRelapsePotential efficacyTherapyMonthsOwn homesPreliminary evidenceRemittersTrialsSubjectsEntire sampleHoursRemission